[Skip to Content]
[Skip to Content Landing]
May 1968

There Is a Third Way

Author Affiliations

Washington, DC

From the Renal and Electrolyte Division, Georgetown University Hospital, Washington, DC.

Arch Intern Med. 1968;121(5):463-465. doi:10.1001/archinte.1968.03640050073015

An important problem which is a source of concern for most academicians and clinical investigators is the role of the medical school and of the academician-investigator in developing, refining, and delivering the fruits of biologic research. Doctor Louis Fieser, inventor of Napalm, said, "An inventor cannot be responsible for how other people use his inventions." I would paraphrase this thought by saying that a clinical investigator cannot be irresponsible about the non-use of his discoveries.

I would like to start with a concrete problem—how to accomplish the management of patients with end-stage renal disease when research has developed not one, but two, effective modes of therapy which are capable of adding years to useful life and rehabilitating a substantial fraction—perhaps even a majority— of those who are treated. Although the problem may seem specialized at first glance, it contains all of the ethical and economic conflicts which apply to other

First Page Preview View Large
First page PDF preview
First page PDF preview